Y. Shibata

The Current Situation and Problems of Re-biopsy in Non-small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations

A. Tsuya, K. Akiyoshi, K. Takeda, 2016 .

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

M. Ando, E. Baba, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The Current Situation and Problems of Re-biopsy in Non-small Cell Lung Cancer (NSCLC) Patients with EGFRMutations

A. Tsuya, K. Akiyoshi, K. Takeda, 2016 .

Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma.

R. Seo, D. Fujimoto, K. Tomii, 2014, Japanese journal of clinical oncology.

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

A. Tsuya, K. Takeda, H. Daga, 2014, Japanese journal of clinical oncology.

Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis

N. Katakami, D. Fujimoto, K. Otsuka, 2014, Clinical & Experimental Metastasis.

Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis

N. Katakami, D. Fujimoto, K. Otsuka, 2014, Clinical & Experimental Metastasis.

Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study.

J. Sakamoto, A. Nakao, K. Oba, 2009, Hepato-gastroenterology.